Rybelsus 14 mg

Rybelsus 14 mg is used with diet and physical activity to improve blood-glucose control in adults with type 2 diabetes who require a higher maintenance dose. Healthcare professionals prescribe it for:

• Improving fasting blood-sugar levels

• Controlling blood-sugar rises after meals

• Supporting improvement in HbA1c

• Continuing oral semaglutide treatment

• Providing additional control after the 7 mg dose

• Use with other prescribed diabetes medicines

• Reducing cardiovascular risk in suitable high-risk adults

The complete Rybelsus treatment regimen is also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have a high risk of cardiovascular death, heart attack or stroke.

This does not mean that Rybelsus replaces blood-pressure medicines, cholesterol treatment or other cardiovascular care. People managing diabetes alongside a heart condition can explore further information about heart health and cardiovascular medicines.

Rybelsus 14 mg provides higher maintenance dose for people who need additional glucose control after using the lower maintenance dose. Its key benefits include:

• Helps reduce fasting blood sugar

• Controls blood-sugar increases after meals

• Supports long-term HbA1c improvement

• Increases glucose-dependent insulin release

• Reduces unnecessary glucagon production

• Helps regulate appetite and food intake

• Provides once-daily oral treatment

• Can complement other diabetes medicines

• Supports cardiovascular risk reduction in suitable patients

Rybelsus provides GLP-1 treatment in tablet form. This offers an alternative for suitable patients who prefer an oral medicine rather than a GLP-1 injection.

Maintaining better blood-glucose control is an important part of protecting the eyes, kidneys, nerves, blood vessels and heart from diabetes-related damage. Regular monitoring and medical follow-up remain necessary even when glucose readings improve.

Semaglutide acts like GLP-1, a hormone naturally released by the digestive system after eating. GLP-1 helps the body coordinate insulin release, glucagon production, digestion and appetite. Rybelsus 14 mg works by:

• Increasing insulin release when glucose is elevated

• Reducing excess glucagon release

• Slowing the movement of food from the stomach

• Reducing appetite and food intake

• Lowering fasting and after-meal glucose levels

Insulin moves glucose from the bloodstream into the body’s cells. Glucagon tells the liver to release stored glucose. Semaglutide strengthens insulin release while reducing unnecessary glucagon production when blood sugar is high.

The medicine also slows stomach emptying. Food enters the small intestine more gradually, which helps reduce sharp blood-sugar increases after meals. This action also contributes to earlier fullness and reduced appetite.

Rybelsus contains an absorption enhancer that helps semaglutide pass through the stomach lining. Food, beverages and other medicines can interfere with this process. Following the administration instructions is therefore essential for consistent absorption.

Rybelsus 14 mg is a maintenance dose for people who require additional blood-sugar control after taking Rybelsus 7 mg once daily for at least 30 days.

The usual dose progression is:

• Rybelsus 3 mg once daily for the first 30 days

• Rybelsus 7 mg once daily from day 31

• Rybelsus 14 mg once daily after at least 30 days at 7 mg when additional control is required

Rybelsus 14 mg is the maximum once-daily dose for the 3 mg, 7 mg and 14 mg formulation. Do not increase the dose further or take an additional tablet.

Take Rybelsus 14 mg:

• Once daily in the morning

• On an empty stomach

• With up to 120 mL of plain water

• At least 30 minutes before food

• At least 30 minutes before another drink

• At least 30 minutes before other oral medicines

Swallow the tablet whole. Do not split, chew, crush or dissolve it. Do not take two 7 mg tablets to create a 14 mg dose unless the healthcare professional and supplied product instructions specifically permit this. The standard direction is one tablet once daily.

If a dose is missed, skip it and take the next dose the following day. Do not take two doses on the same day.

Different oral semaglutide formulations are available in certain markets. Their strength numbers are not directly interchangeable. Always follow the product name, formulation and strength written on the prescription.

Common Side Effects: Rybelsus 14 mg can cause nausea, diarrhoea, abdominal discomfort, vomiting, reduced appetite and constipation. Indigestion, bloating, burping, gas and acid reflux can also occur. Digestive reactions can become more noticeable after the dose is increased. Contact the healthcare professional if these effects continue, become difficult to manage or prevent normal eating and drinking.

Serious Side Effects: Seek medical attention for severe or persistent abdominal pain, particularly when it spreads to the back, because this can indicate pancreatitis. Prompt assessment is also required for sudden vision changes, severe vomiting or diarrhoea, reduced urination, significant dehydration, yellow skin or eyes, intense upper-abdominal pain or symptoms of severe low blood sugar. Facial swelling, throat swelling, breathing difficulty or another serious allergic reaction requires emergency care.

Do not start Rybelsus 14 mg without a complete medical assessment if any of the following apply:

• Personal history of medullary thyroid carcinoma

• Family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2

• Serious allergy to semaglutide

• Allergy to another tablet ingredient

• Pregnancy or planned pregnancy

• Breastfeeding

• Severe gastroparesis

• Type 1 diabetes

• Diabetic ketoacidosis

• Previous pancreatitis

• Serious diabetic retinopathy

• Children and adolescents

Women planning pregnancy are normally instructed to stop semaglutide at least two months before trying to conceive. A healthcare professional should arrange a suitable diabetes-management plan during this period.

Tell the doctor or pharmacist about every medicine, supplement and herbal product being used. Important interactions include:

• Insulin

• Sulfonylureas

• Levothyroxine

• Warfarin

• Closely monitored oral medicines

• Other GLP-1 receptor agonists

• Other semaglutide products

Using Rybelsus with insulin or a sulfonylurea can increase the risk of hypoglycaemia. The accompanying diabetes medicine can require a dosage adjustment and closer glucose monitoring.

Rybelsus delays stomach emptying and can affect the absorption of oral medicines. This is particularly important for medicines that require precise blood levels or regular laboratory tests.

Wait at least 30 minutes after taking Rybelsus before taking another oral medicine unless different instructions have been provided. Do not combine Rybelsus with another GLP-1 receptor agonist or semaglutide product without clear medical directions.

• Keep Rybelsus in its original packaging.

• Store the tablets in a dry place.

• Protect them from moisture.

• Keep the container tightly closed.

• Follow the storage temperature printed on the pack.

• Do not transfer tablets into an unlabelled container.

• Keep away from children and pets.

• Do not use damaged or discoloured tablets.

• Check the expiry date before use.

• Dispose of expired tablets responsibly.

The bottle presentation is stored at 20°C to 25°C, with permitted short-term temperature excursions between 15°C and 30°C. Keep the tablets in the original container until they are required.